United Therapeutics
United Therapeutics terminates oral pulmonary arterial hypertension drug following Phase 3 failure
April 9, 2019Manufacturing and Production, Research and Development Tyvaso, United Therapeutics, pharma, pulmonary arterial hypertension
United Therapeutics has revealed in a short announcement that, because its pulmonary arterial hypertension (PAH) therapy failed to meet its …
United Therapeutics buys Arena’s hypertension drug ralinepag in deal worth $1.2 billion
November 16, 2018Medical Communications Arena, PAH, United Therapeutics, deal sales, hypertension
US pharma firm United Therapeutics has agreed to by Arena Pharmaceuticals experimental pulmonary arterial hypertension (PAH) drug ralinepag in a …
Nice rejects United Therapeutics’ cancer drug
July 15, 2016Medical Communications, Research and Development NICE, United Therapeutics, Unituxin, neuroblastoma
The National Institute for Health and Care Excellence (Nice) rejected United Therapeutics’ (Nasdaq: UTHR) Unituxin (dinutuximab) in combination therapy to …
Latest content
Five Facts about cardiovascular disease
August 9, 2026
